5.90
+0.045(+0.77%)
Currency In USD
| Previous Close | 5.85 |
| Open | 5.79 |
| Day High | 5.98 |
| Day Low | 5.75 |
| 52-Week High | 20 |
| 52-Week Low | 3.94 |
| Volume | 25,142 |
| Average Volume | 79,600 |
| Market Cap | 18.91M |
| PE | -0.5 |
| EPS | -11.84 |
| Moving Average 50 Days | 6.68 |
| Moving Average 200 Days | 8.52 |
| Change | 0.05 |
Passage Bio to Present at Guggenheim Securities 2nd Annual Healthcare Innovation Conference
GlobeNewswire Inc.
Nov 05, 2025 12:00 PM GMT
PHILADELPHIA, Nov. 05, 2025 (GLOBE NEWSWIRE) -- Passage Bio, Inc. (NASDAQ: PASG), a clinical stage genetic medicines company focused on improving the lives of patients with neurodegenerative diseases, today announced that Will Chou, M.D., president
Passage Bio to Participate in Chardan’s 9th Annual Genetic Medicines Conference
GlobeNewswire Inc.
Oct 14, 2025 11:00 AM GMT
PHILADELPHIA, Oct. 14, 2025 (GLOBE NEWSWIRE) -- Passage Bio, Inc. (NASDAQ: PASG), a clinical stage genetic medicines company focused on improving the lives of patients with neurodegenerative diseases, today announced that Will Chou, M.D., president
Passage Bio to Participate in H.C. Wainwright 27th Annual Global Investment Conference
GlobeNewswire Inc.
Aug 28, 2025 11:00 AM GMT
PHILADELPHIA, Aug. 28, 2025 (GLOBE NEWSWIRE) -- Passage Bio, Inc. (NASDAQ: PASG), a clinical stage genetic medicines company focused on improving the lives of patients with neurodegenerative diseases, today announced that management will participat